Study authors assessed the long-term effects of secukinumab on fatigue in patients with ankylosing spondylitis in the MEASURE 1 and MEASURE 2 trials.
Investigators compared differences in pain reports between patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis to assess how pain sensitivity was associated with disease and health outcomes.
Researchers determined the causal associations between genetically predicted TNF-α, IL-12p70, and IL-17 levels and risk for psoriatic arthritis.
Investigators examined the long-term association between disease activity and disability in axSpA.
For adults with psoriatic diseases, the likelihood of developing bone fractures is increased.
Researchers assessed the risk for osteoarthritis in patients with PsA compared with those with psoriasis and the general population.
Researchers compared the effect of psoriatic arthritis and rheumatoid arthritis on objective and subjective parameters of hand function.
Researchers evaluated the prevalence of axial involvement in early peripheral spondyloarthritis and whether inflammation predicted relapse on treatment withdrawal.
Study authors determined the association between disease activity and the subsequent 2-year spinal radiographic progression in axial spondyloarthritis.
The FDA has accepted for review the BLA for AVT02 (Alvotech), a proposed biosimilar to adalimumab; AbbVie, with high concentration (100mg/mL) dosage forms.